E
Kalaris Therapeutics, Inc. KLRS
$4.53 -$0.10-2.05% NASDAQ
Recommendation
Prev Close
$4.63
Volume
338,039
Avg Vol (90D)
235,854
Market Cap
$86.50M
Dividend & Yield
--
52-Week Range
$2.14 - $12.90
P/E (TTM)
--
EPS (TTM)
-$3.12
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Kalaris Therapeutics (NASDAQ:KLRS) Receives "Sell (E)" Rating from Weiss Ratings
10/10/2025 - MarketBeat
Kalaris Therapeutics (KLRS, $4.63) entered Downtrend as Momentum indicator drops below 0 level on Oct 09, 2025
10/10/2025 - Tickeron - Stocks
Kalaris Therapeutics (KLRS, $4.63) Moving Average Convergence Divergence (MACD) Histogram turned negative on October 9, 2025
10/10/2025 - Tickeron - Stocks
Kalaris Therapeutics (KLRS, $6.59) RSI Indicator left the overbought zone on October 08, 2025
10/9/2025 - Tickeron - Stocks
Kalaris Therapeutics (KLRS, $8.03) RSI Indicator left the overbought zone on October 06, 2025
10/7/2025 - Tickeron - Stocks
Kalaris Therapeutics (KLRS, $8.03) price may drop as it broke higher Bollinger Band on Oct 06, 2025
10/7/2025 - Tickeron - Stocks
Kalaris Therapeutics (KLRS, $6.64) RSI Indicator left the overbought zone on October 03, 2025
10/4/2025 - Tickeron - Stocks
Kalaris Therapeutics (NASDAQ:KLRS) Upgraded at Wall Street Zen
10/4/2025 - MarketBeat
Kalaris Therapeutics Inc. (NASDAQ:KLRS) Short Interest Update
10/4/2025 - MarketBeat
Kalaris Therapeutics (KLRS, $7.09) price may drop as it broke higher Bollinger Band on Oct 02, 2025
10/3/2025 - Tickeron - Stocks
Kalaris Therapeutics (KLRS, $7.09) RSI Indicator left the overbought zone on October 02, 2025
10/3/2025 - Tickeron - Stocks
Kalaris Therapeutics (KLRS, $5.78) RSI Indicator left the overbought zone on September 30, 2025
10/1/2025 - Tickeron - Stocks
Private equity firms in Kalaris Therapeutics, Inc. (NASDAQ:KLRS) are its biggest bettors, and their bets paid off as stock gained 24% last week
9/28/2025 - Simply Wall St
Kalaris Therapeutics (KLRS, $5.61) RSI Indicator left the overbought zone on September 26, 2025
9/27/2025 - Tickeron - Stocks
Kalaris Therapeutics (KLRS, $5.61) Moving Average Convergence Divergence (MACD) Histogram turned positive on September 26, 2025
9/27/2025 - Tickeron - Stocks
Kalaris Therapeutics (KLRS, $5.61) price may drop as it broke higher Bollinger Band on Sep 26, 2025
9/27/2025 - Tickeron - Stocks
Leerink Partners Remains a Buy on Kalaris Therapeutics (KLRS)
9/17/2025 - TipRanks Financial Blog
Kalaris Therapeutics (KLRS) Receives a Buy from Raymond James
9/16/2025 - TipRanks Financial Blog
UPDATE -- Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 ...
9/15/2025 - GuruFocus
UPDATE Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular Degeneration
9/15/2025 - Globe Newswire
Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in ...
9/15/2025 - GuruFocus
Kalaris Therapeutics (KLRS) Initiates Crucial Study for Macular Degeneration Therapy
9/15/2025 - GuruFocus
Kalaris Therapeutics now enrolling Phase 1b/2 MAD study of TH103
9/15/2025 - The Fly
Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular Degeneration
9/15/2025 - Globe Newswire
Kalaris Therapeutics (NASDAQ:KLRS) Trading 0.9% Higher - Still a Buy?
9/12/2025 - MarketBeat
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
--
EBIT (TTM)
--
Net Income (TTM)
--
Balance Sheet
Total Assets (Q)
$92.84M
Total Debt (Q)
$0.00
Total Liabilities (Q)
$39.73M
Book Value Per Share (Q)
$2.84
Cash Flow
Cash from Operations (TTM)
--
Cash from Investing (TTM)
--
Cash from Financing (TTM)
--
Net Change in Cash (TTM)
--
Filings
Filing Date
Wednesday, August 13, 2025
Period Date
Monday, June 30, 2025
Next Filing
Week of Jan 12 and 16 (est)
Price History
Loading...
Beta
--
7-Day Total Return
-25.37%
30-Day Total Return
27.25%
60-Day Total Return
87.19%
90-Day Total Return
47.08%
Year to Date Total Return
-60.51%
1-Year Total Return
--
2-Year Total Return
--
3-Year Total Return
--
5-Year Total Return
--
52-week Low
Aug 14, 2025 - $2.14
52-week High
Mar 20, 2025 - $12.90
Valuation
Market Cap
$86.50M - Micro Cap
Enterprise Value
-$1.93M
Price/Sales (TTM)
--
Price/Book (Q)
1.63
Dividends and Shares
Shares Outstanding
18.70
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
kalaristx.com
Phone Number
Address
628 Middlefield Road
Palo Alto, CA 94301
Country
United States
Year Founded
2019
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Kalaris Therapeutics, Inc., a clinical-stage ophthalmology biotech company, engages in developing therapies for the treatment of neovascular retinal diseases. Kalaris Therapeutics, Inc. was... more
NASDAQ 10/10/2025 3:27PM Eastern Quotes delayed